Literature DB >> 7829632

Tamoxifen inhibits growth, migration, and invasion of human follicular and papillary thyroid cancer cells in vitro and in vivo.

T Hoelting1, A E Siperstein, Q Y Duh, O H Clark.   

Abstract

Prognosis of differentiated thyroid cancer is best in young women. It has been proposed that sex steroids protect premenopausal women from aggressive thyroid malignancies. Some thyroid tissues have estrogen receptors, and estrogen stimulates human thyroid cells. Tamoxifen is thought to exert its antiproliferative effects mainly by blocking estrogen stimulation. However, recently, mechanisms independent of estrogen interactions were found to be important for the favorable effect. We investigated the effect of tamoxifen on the growth, migration, and invasion in three follicular thyroid cancer cell lines (FTC133, primary; FTC236, lymph node; and FTC238, lung metastasis) from one patient and two papillary lines (PTC-UC1 and PTC-UC3). Growth was measured by dimethylthiazol-diphenyltetrazolium bromide assays, and migration was determined by the ability of cells to penetrate 8-microns pore membranes, which were covered by Matrigel for invasion assays. For in vivo experiments, we used xenografts of FTC133 in nude mice. Tamoxifen (1.5 mumol/L) inhibited the growth of all thyroid cancer cell lines (FTC133, 59%; FTC236, 42%; FTC238, 46%; P < 0.01). This effect was less pronounced in PTC-UC1 (25%) and PTC-UC3 (19%; P < 0.006) cell lines. Tamoxifen also inhibited migration and invasion of FTC more than PTC. Invasion of FTC133 was inhibited by 36% (P < 0.01), FTC236 by 30%, and FTC238 by 32%. Immunohistochemistry showed no estrogen receptors in any cell line. Also, estradiol had no significant effect on the growth, migration, or invasion of FTC or PTC. Tamoxifen treatment inhibited the growth of FTC133 xenografts in nude mice by 52% compared to that in placebo-treated controls (P < 0.002). In conclusion, tamoxifen inhibited the growth, migration, and invasion of differentiated thyroid cancer cells in vitro and in vivo. This was not reversed by estrogen. Tamoxifen acts independently of estrogen interactions and may be useful as an adjuvant treatment for some differentiated human thyroid malignancies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7829632     DOI: 10.1210/jcem.80.1.7829632

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects.

Authors:  N J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  Technical considerations for studying cancer metastasis in vivo.

Authors:  D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

3.  Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase.

Authors:  S Spence; G Rena; M Sullivan; S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

4.  Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers.

Authors:  L Soroceanu; T J Manning; H Sontheimer
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

5.  MiR-26a inhibits thyroid cancer cell proliferation by targeting ARPP19.

Authors:  Yanping Gong; Wenshuang Wu; Xiuhe Zou; Feng Liu; Tao Wei; Jingqiang Zhu
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

6.  Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression.

Authors:  Xiao-Min Yu; Renata Jaskula-Sztul; Maria R Georgen; Zviadi Aburjania; Yash R Somnay; Glen Leverson; Rebecca S Sippel; Ricardo V Lloyd; Brian P Johnson; Herbert Chen
Journal:  Clin Cancer Res       Date:  2016-02-04       Impact factor: 12.531

7.  Innovative in vitro chemo-hormonal drug therapy for refractory thyroid carcinomas.

Authors:  Tae-Yon Sung; Sung Ho Choi; Jung Min Lee; Jong Ju Jeong; Sang-Wook Kang; Woong Youn Chung
Journal:  J Korean Med Sci       Date:  2012-06-29       Impact factor: 2.153

8.  Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells.

Authors:  Juan A Rivera; Haydar Alturaihi; Ujendra Kumar
Journal:  J Carcinog       Date:  2005-07-14

Review 9.  Tamoxifen non-estrogen receptor mediated molecular targets.

Authors:  Tatiana Bogush; Evgeny Dudko; Elena Bogush; Boris Polotsky; Sergei Tjulandin; Mikhail Davydov
Journal:  Oncol Rev       Date:  2012-10-04

Review 10.  Tamoxifen and oxidative stress: an overlooked connection.

Authors:  Nermin S Ahmed; Marek Samec; Alena Liskova; Peter Kubatka; Luciano Saso
Journal:  Discov Oncol       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.